Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
- 26 February 2022
- journal article
- research article
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 100, 33-45
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2012
- Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2012
- Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancerEuropean Journal of Cancer, 2012
- High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective AnalysisJournal of Clinical Oncology, 2011
- PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant gliomaJournal of Thrombosis and Haemostasis, 2010
- The Development of Clinical Practice Guidelines and Guidance Statements of the American College of Physicians: Summary of MethodsAnnals of Internal Medicine, 2010
- Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies GroupJournal of Clinical Oncology, 2009
- Understanding and managing the possible adverse effects associated with bevacizumabAmerican Journal of Health-System Pharmacy, 2009
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Incidence and management of bevacizumab-related toxicities in colorectal cancerExpert Opinion on Drug Safety, 2006